Bill joined Venrock in 2006 from Biogen Idec, where he was most recently executive chairman. He currently serves as Chairman of the Board at Fate Therapeutics, Receptos, Illumina and Neurocrine Biosciences. Bill joined Idec Pharmaceuticals at its founding in 1986 and grew it to a multi-billion-dollar market valuation company, while serving as Chairman and CEO. He was at Biogen Idec from the merger of the two companies in 2003, through the end of 2005. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and also served in a scientific capacity at the company.
Adding to his corporate background, Bill held various faculty positions at MIT, won the award for “Excellence in the Teaching of Chemistry” at Harvard and is an Alfred P. Sloan Fellow. He is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology.
Bill holds a B.S. in Chemistry from the Massachusetts Institute of Technology and received his M.A. and Ph.D. in Chemistry from Harvard University.